← All trials
NCT05303961
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 7, 2016
- Primary completion
- Nov 11, 2016
- Completion date
- Nov 11, 2016
- First posted
- Mar 31, 2022
- Last posted
- Mar 31, 2022
- Enrollment
- 56
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Samjin Pharmaceutical Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.